| Year |
Citation |
Score |
| 2023 |
Hu Q, Liao Y, Cao J, Fang B, Yun S, Kinose F, Haura E, Lawrence H, Doebele R, Koomen J, Rix U. Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib. Chembiochem : a European Journal of Chemical Biology. e202200766. PMID 36922348 DOI: 10.1002/cbic.202200766 |
0.3 |
|
| 2021 |
Palve V, Knezevic CE, Bejan DS, Luo Y, Li X, Novakova S, Welsh EA, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Cohen MS, Lawrence HR, Rix U. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell Chemical Biology. PMID 34329582 DOI: 10.1016/j.chembiol.2021.07.008 |
0.312 |
|
| 2021 |
Wright GM, Gimbrone NT, Sarcar B, Percy TR, Gordián ER, Kinose F, Sumi NJ, Rix U, Cress WD. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines. Plos One. 16: e0252927. PMID 34138895 DOI: 10.1371/journal.pone.0252927 |
0.304 |
|
| 2021 |
Schubert L, Le AT, Estrada-Bernal A, Doak AE, Yoo M, Ferrara SE, Goodspeed A, Kinose F, Rix U, Tan AC, Doebele RC. . Molecular Pharmacology. PMID 33795352 DOI: 10.1124/molpharm.120.000207 |
0.312 |
|
| 2020 |
Palve V, Liao Y, Remsing Rix LL, Rix U. Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Seminars in Cancer Biology. PMID 32044472 DOI: 10.1016/J.Semcancer.2020.02.003 |
0.33 |
|
| 2020 |
Cocco E, Lee JE, Kannan S, Schram AM, Won HH, Shifman S, Kulick A, Baldino L, Toska E, Arena S, Mussolin B, Kannan R, Vasan N, Gorelick AN, Berger MF, ... ... Rix U, et al. Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors Cancer Research. 80: 5680-5680. DOI: 10.1158/1538-7445.Am2020-5680 |
0.367 |
|
| 2020 |
Remsing Rix L, Sumi N, Bryant A, Desai B, Li X, Welsh E, Fang B, Kuenzi B, Antonia S, Lovly C, Koomen J, Marusyk A, Haura E, Rix U. B40 IGF-Binding Protein-Mediated Sensitization of EGFR-Mutant NSCLC Cells to Osimertinib by Cancer-Associated Fibroblast Journal of Thoracic Oncology. 15: S38. DOI: 10.1016/J.Jtho.2019.12.104 |
0.329 |
|
| 2019 |
Xie M, Zheng H, Madan-Lala R, Dai W, Gimbrone NT, Chen Z, Kinose F, Blackstone SA, Smalley KSM, Cress WD, Haura EB, Rix U, Beg AA. MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer. Cancer Research. PMID 31362929 DOI: 10.1158/0008-5472.Can-19-0698 |
0.41 |
|
| 2019 |
Sarcar B, Gimbrone NT, Wright G, Remsing Rix LL, Gordian ER, Rix U, Chiappori AA, Reuther GW, Santiago-Cardona PG, Muñoz-Antonia T, Cress WD. Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model. Febs Open Bio. PMID 31314158 DOI: 10.1002/2211-5463.12702 |
0.358 |
|
| 2019 |
Sumi NJ, Ctortecka C, Hu Q, Bryant AT, Fang B, Remsing Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. Cell Chemical Biology. PMID 31257184 DOI: 10.1016/J.Chembiol.2019.06.003 |
0.41 |
|
| 2019 |
Faião-Flores F, Emmons MF, Durante MA, Kinose F, Saha B, Fang B, Koomen JM, Chellappan SP, Maria-Engler SS, Rix U, Licht JD, Harbour JW, Smalley KSM. HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31227503 DOI: 10.1158/1078-0432.Ccr-18-3382 |
0.329 |
|
| 2019 |
Ramello MC, Benzaïd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, Pabón-Saldaña M, Darville L, Fang B, Rix U, Yoder S, Berglund A, Koomen JM, Haura EB, Abate-Daga D. An immunoproteomic approach to characterize the CAR interactome and signalosome. Science Signaling. 12. PMID 30755478 DOI: 10.1126/Scisignal.Aap9777 |
0.326 |
|
| 2019 |
Kuenzi BM, Remsing Rix LL, Kinose F, Kroeger JL, Lancet JE, Padron E, Rix U. Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. Scientific Reports. 9: 606. PMID 30679640 DOI: 10.1038/S41598-018-37174-6 |
0.387 |
|
| 2019 |
Majumder A, Boutchueng-Djidjou M, Kim J, Sumi N, Rix U, Haura EB. Abstract C114: Cancer cell induced activation of associated fibroblasts is PDGFR-mediated Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C114 |
0.415 |
|
| 2019 |
Rix LLR, Sumi NJ, Bryant AT, Li X, Welsh EA, Fang B, Kuenzi BM, Antonia SJ, Marusyk A, Lovly CM, Koomen JM, Haura EB, Rix U. Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C110 |
0.433 |
|
| 2019 |
Xie M, Zheng H, Madan-Lala R, Dai W, Gimbrone NT, Chen Z, Kinose F, Blackstone SA, Smalley KSM, Cress D, Haura EB, Rix U, Beg AA. Abstract B072: MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer Molecular Cancer Therapeutics. DOI: 10.1158/1535-7163.Targ-19-B072 |
0.329 |
|
| 2019 |
Deng O, Dash S, Nepomuceno T, Han MD, Fang B, Marchion D, Monteiro AN, Rix U. Abstract B022: PARP1 complex composition as a predictor of response to PARP inhibitors in BRCA-linked ovarian carcinoma Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B022 |
0.387 |
|
| 2019 |
Palve V, Knezevic C, Luo Y, Li X, Novakova S, Welsh E, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Lawrence HR, Rix U. Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B021 |
0.431 |
|
| 2018 |
Boutchueng-Djidjou M, Rix U, Haura EB. Bidirectional Adaptive Signaling between cancer and stromal cells: mechanisms and therapeutics. Expert Review of Proteomics. 15: 697-699. PMID 30251554 DOI: 10.1080/14789450.2018.1521276 |
0.304 |
|
| 2018 |
Nerlakanti N, Yao J, Nguyen DT, Patel AK, Eroshkin AM, Lawrence HR, Ayaz M, Kuenzi BM, Agarwal N, Chen Y, Gunawan S, Karim RM, Berndt N, Puskas J, Magliocco AM, ... ... Rix U, et al. Targeting the BRD4-HOXB13 Co-regulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics. PMID 30242092 DOI: 10.1158/1535-7163.Mct-18-0602 |
0.405 |
|
| 2018 |
Ctortecka C, Palve V, Kuenzi BM, Fang B, Sumi NJ, Izumi V, Novakova S, Kinose F, Remsing Rix LL, Haura EB, Koomen JM, Rix U. Functional proteomics and deep network interrogation reveal a complex mechanism of action of midostaurin in lung cancer cells. Molecular & Cellular Proteomics : McP. PMID 30217950 DOI: 10.1074/Mcp.Ra118.000713 |
0.421 |
|
| 2018 |
Palve V, Kuenzi BM, Rix U. Unraveling the rewired network. Nature Chemical Biology. PMID 29942077 DOI: 10.1038/S41589-018-0083-7 |
0.352 |
|
| 2018 |
Djidjou MB, Kim J, Han K, Wright G, Majumder A, Fang B, Koomen J, Rix LLR, Rix U, Haura E. Abstract 5089: A quantitative proteomic survey reveals mechanisms of the bi-directional signaling between lung fibroblasts and lung cancer cells Cancer Research. 78: 5089-5089. DOI: 10.1158/1538-7445.Am2018-5089 |
0.406 |
|
| 2017 |
Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE. Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget. 8: 103014-103031. PMID 29262541 DOI: 10.18632/Oncotarget.20488 |
0.403 |
|
| 2017 |
Hoffman MA, Fang B, Haura EB, Rix U, Koomen JM. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. Journal of Proteome Research. PMID 29164889 DOI: 10.1021/Acs.Jproteome.7B00329 |
0.33 |
|
| 2017 |
Verduzco D, Kuenzi BM, Kinose F, Sondak VK, Eroglu Z, Rix U, Smalley KSM. Ceritinib enhances the efficacy of trametinib in BRAF/NRAS-wild type melanoma cell lines. Molecular Cancer Therapeutics. PMID 29133622 DOI: 10.1158/1535-7163.Mct-17-0196 |
0.391 |
|
| 2017 |
Phadke M, Rix LLR, Smalley I, Bryant AT, Luo Y, Lawrence HR, Schaible BJ, Chen YA, Rix U, Smalley KSM. Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Molecular Oncology. PMID 29112787 DOI: 10.1002/1878-0261.12152 |
0.389 |
|
| 2017 |
Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, Boyle TA, Koomen JM, Haura EB, Rix U. Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nature Chemical Biology. PMID 28991240 DOI: 10.1038/Nchembio.2489 |
0.427 |
|
| 2017 |
Wright G, Golubeva V, Remsing Rix LL, Berndt N, Luo Y, Ward GA, Gray JE, Schönbrunn E, Lawrence HR, Monteiro ANA, Rix U. Dual targeting of WEE1 and PLK1 by AZD1775 elicits single agent cellular anticancer activity. Acs Chemical Biology. PMID 28557434 DOI: 10.1021/Acschembio.7B00147 |
0.428 |
|
| 2017 |
Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar S, Glogowska MJ, Smith MA, Kako SL, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, et al. EGFR mediates responses to small molecule drugs targeting oncogenic fusion kinases. Cancer Research. PMID 28428274 DOI: 10.1158/0008-5472.Can-17-0109 |
0.411 |
|
| 2017 |
Gray JE, Tanvetyanon T, Creelan BC, Antonia SJ, Haura EB, Williams CC, Yaseen R, Schell MJ, Godin R, Rix U, Monteiro A. Phase II trial of AZD1775 in combination with carboplatin and paclitaxel in stage IV squamous cell lung cancer (sqNSCLC): Preliminary results. Journal of Clinical Oncology. 35: e20672-e20672. DOI: 10.1200/Jco.2017.35.15_Suppl.E20672 |
0.309 |
|
| 2017 |
Sumi NJ, Fang B, Rix LL, Ayaz M, Kinose F, Welsh EA, Eschrich SA, Lawrence HR, Koomen JM, Haura EB, Rix U. Abstract 221: Integrated functional proteomics of MET/VEGFR inhibitors reveals complex mechanism of action of foretinib in NSCLC Cancer Research. 77: 221-221. DOI: 10.1158/1538-7445.Am2017-221 |
0.441 |
|
| 2016 |
Knezevic CE, Wright G, Remsing Rix LL, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chemical Biology. PMID 27866910 DOI: 10.1016/J.Chembiol.2016.10.011 |
0.38 |
|
| 2016 |
Jhuraney A, Woods NT, Wright G, Rix L, Kinose F, Kroeger JL, Remily-Wood E, Cress WD, Koomen JM, Brantley SG, Gray JE, Haura EB, Rix U, Monteiro AN. PAXIP1 potentiates the combination of WEE1 inhibitor AZD1775 and platinum agents in lung cancer. Molecular Cancer Therapeutics. PMID 27196765 DOI: 10.1158/1535-7163.Mct-15-0182 |
0.382 |
|
| 2016 |
Li J, Fang B, Kinose F, Bai Y, Kim JY, Chen YA, Rix U, Koomen JM, Haura EB. Target identification in small cell lung cancer via integrated phenotypic screening and activity-based protein profiling. Molecular Cancer Therapeutics. PMID 26772203 DOI: 10.1158/1535-7163.Mct-15-0444 |
0.412 |
|
| 2015 |
Sumi NJ, Kuenzi BM, Knezevic CE, Remsing Rix LL, Rix U. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. Acs Chemical Biology. PMID 26390342 DOI: 10.1021/Acschembio.5B00368 |
0.402 |
|
| 2015 |
Haura EB, Beg AA, Rix U, Antonia S. Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies. Cancer Immunology Research. 3: 714-20. PMID 26081226 DOI: 10.1158/2326-6066.Cir-15-0094 |
0.316 |
|
| 2015 |
Ma Y, Rix LR, Zhang Q, Balasis ME, Komrokji RS, Rix U, List AF, Padron E. Pacritinib (PAC) Synergistically Potentiates Azacitidine (5AZA) Cytotoxicity in Chronic Myelomonocytic Leukemia (CMML) Blood. 126: 1658-1658. DOI: 10.1182/Blood.V126.23.1658.1658 |
0.375 |
|
| 2015 |
Kuenzi BM, Rix LLR, Kunigal SS, Kinose F, Knezevic CE, Wright G, Kroeger JL, Lancet JE, Padron E, Rix U. Abstract 675: Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia Cancer Research. 75: 675-675. DOI: 10.1158/1538-7445.Am2015-675 |
0.345 |
|
| 2015 |
Knezevic C, Wright G, Kuenzi B, Rix LR, Luo Y, Lawrence H, Rix U. Abstract A71: Differential proteome-wide target profiles of clinical poly(ADP-ribose) polymerase inhibitors in breast cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A71 |
0.4 |
|
| 2014 |
Bai Y, Kim JY, Watters JM, Fang B, Kinose F, Song L, Koomen JM, Teer JK, Fisher K, Chen YA, Rix U, Haura EB. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Research. 74: 7217-28. PMID 25348954 DOI: 10.1158/0008-5472.Can-14-0505 |
0.394 |
|
| 2014 |
Haura EB, Rix U. Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing. Journal of the National Cancer Institute. 106. PMID 25214562 DOI: 10.1093/Jnci/Dju250 |
0.374 |
|
| 2014 |
Gridling M, Ficarro SB, Breitwieser FP, Song L, Parapatics K, Colinge J, Haura EB, Marto JA, Superti-Furga G, Bennett KL, Rix U. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics. Molecular Cancer Therapeutics. 13: 2751-62. PMID 25189542 DOI: 10.1158/1535-7163.Mct-14-0152 |
0.301 |
|
| 2014 |
Yang H, Lawrence HR, Kazi A, Gevariya H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence NJ, Sebti SM. Dual aurora a and jak2 kinase blockade effectively suppresses malignant transformation Oncotarget. 5: 2947-2961. PMID 24930769 DOI: 10.18632/Oncotarget.1615 |
0.382 |
|
| 2014 |
Remsing Rix LL, Kuenzi BM, Luo Y, Remily-Wood E, Kinose F, Wright G, Li J, Koomen JM, Haura EB, Lawrence HR, Rix U. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells Acs Chemical Biology. 9: 353-358. PMID 24215125 DOI: 10.1021/Cb400660A |
0.422 |
|
| 2014 |
Jhuraney A, Woods NT, Kinose F, Cress DW, Gray JE, Haura EB, Rix U, Monteiro AN. Abstract 2414: Overexpression of PAXIP1 potentiates WEE1 inhibitor action in lung cancer cells Cancer Research. 74: 2414-2414. DOI: 10.1158/1538-7445.Am2014-2414 |
0.407 |
|
| 2014 |
Sebti SM, Yang H, Lawrence H, Kazi A, Gervaria H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence N. Abstract 1750: Combined blockade of Aurora A and JAK2 kinase is highly effective at inhibiting malignant transformation Cancer Research. 74: 1750-1750. DOI: 10.1158/1538-7445.Am2014-1750 |
0.396 |
|
| 2013 |
Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, Bronk C, Remsing Rix LL, Beg AA, Rix U, Eschrich SA, Koomen JM, Haura EB. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 110: 12414-9. PMID 23836654 DOI: 10.1073/Pnas.1220674110 |
0.377 |
|
| 2013 |
Radic B, Rix U, Kubicek S, Superti-Furga G. Abstract 5038: Probing network fragilities in neuroblastoma by synergistic drug combinations. Cancer Research. 73: 5038-5038. DOI: 10.1158/1538-7445.Am2013-5038 |
0.389 |
|
| 2005 |
Zheng JT, Rix U, Zhao L, Mattingly C, Adams V, Chen Q, Rohr J, Yang KQ. Cytotoxic activities of new jadomycin derivatives. The Journal of Antibiotics. 58: 405-8. PMID 16156517 DOI: 10.1038/Ja.2005.51 |
0.561 |
|
| 2005 |
Chen YH, Wang CC, Greenwell L, Rix U, Hoffmeister D, Vining LC, Rohr J, Yang KQ. Functional analyses of oxygenases in jadomycin biosynthesis and identification of JadH as a bifunctional oxygenase/dehydrase Journal of Biological Chemistry. 280: 22508-22514. PMID 15817470 DOI: 10.1074/Jbc.M414229200 |
0.573 |
|
| 2005 |
Rix U, Wang C, Chen Y, Lipata FM, Rix LLR, Greenwell LM, Vining LC, Yang K, Rohr J. The oxidative ring cleavage in jadomycin biosynthesis: A multistep oxygenation cascade in a biosynthetic black box Chembiochem. 6: 838-845. PMID 15776503 DOI: 10.1002/Cbic.200400395 |
0.575 |
|
| 2005 |
Zhu L, Ostash B, Rix U, Nur-E-Alam M, Mayers A, Luzhetskyy A, Mendez C, Salas JA, Bechthold A, Fedorenko V, Rohr J. Identification of the function of gene lndM2 encoding a bifunctional oxygenase-reductase involved in the biosynthesis of the antitumor antibiotic landomycin E by Streptomyces globisporus 1912 supports the originally assigned structure for landomycinone. The Journal of Organic Chemistry. 70: 631-8. PMID 15651811 DOI: 10.1021/Jo0483623 |
0.573 |
|
| 2004 |
Ostash B, Rix U, Rix LL, Liu T, Lombo F, Luzhetskyy A, Gromyko O, Wang C, Braña AF, Méndez C, Salas JA, Fedorenko V, Rohr J. Generation of new landomycins by combinatorial biosynthetic manipulation of the LndGT4 gene of the landomycin E cluster in S. globisporus. Chemistry & Biology. 11: 547-55. PMID 15123249 DOI: 10.1016/J.Chembiol.2004.03.011 |
0.562 |
|
| 2004 |
Rix U, Zheng J, Remsing Rix LL, Greenwell L, Yang K, Rohr J. The dynamic structure of jadomycin B and the amino acid incorporation step of its biosynthesis. Journal of the American Chemical Society. 126: 4496-7. PMID 15070349 DOI: 10.1021/Ja031724O |
0.524 |
|
| 2003 |
Remsing LL, González AM, Nur-e-Alam M, Fernández-Lozano MJ, Braña AF, Rix U, Oliveira MA, Méndez C, Salas JA, Rohr J. Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. Journal of the American Chemical Society. 125: 5745-53. PMID 12733914 DOI: 10.1021/Ja034162H |
0.585 |
|
| 2003 |
Rix U, Remsing LL, Hoffmeister D, Bechthold A, Rohr J. Urdamycin L: a novel metabolic shunt product that provides evidence for the role of the urdM gene in the urdamycin A biosynthetic pathway of Streptomyces fradiae TU 2717. Chembiochem : a European Journal of Chemical Biology. 4: 109-11. PMID 12512084 DOI: 10.1002/Cbic.200390002 |
0.537 |
|
| 2002 |
Rix U, Fischer C, Remsing LL, Rohr J. Modification of post-PKS tailoring steps through combinatorial biosynthesis. Natural Product Reports. 19: 542-80. PMID 12430723 DOI: 10.1039/B103920M |
0.493 |
|
| 2002 |
Trefzer A, Blanco G, Remsing L, Künzel E, Rix U, Lipata F, Braña AF, Méndez C, Rohr J, Bechthold A, Salas JA. Rationally designed glycosylated premithramycins: hybrid aromatic polyketides using genes from three different biosynthetic pathways. Journal of the American Chemical Society. 124: 6056-62. PMID 12022840 DOI: 10.1021/Ja017385L |
0.562 |
|
| 2002 |
Macky TA, Oelkers C, Rix U, Heredia ML, Künzel E, Wimberly M, Rohrer B, Crosson CE, Rohr J. Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. Journal of Medicinal Chemistry. 45: 1122-7. PMID 11855992 DOI: 10.1021/Jm010511B |
0.552 |
|
| 2002 |
Remsing LL, Garcia-Bernardo J, Gonzalez A, Künzel E, Rix U, Braña AF, Bearden DW, Méndez C, Salas JA, Rohr J. Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathway. Journal of the American Chemical Society. 124: 1606-14. PMID 11853433 DOI: 10.1021/Ja0105156 |
0.585 |
|
| 2000 |
Trefzer A, Hoffmeister D, Künzel E, Stockert S, Weitnauer G, Westrich L, Rix U, Fuchser J, Bindseil KU, Rohr J, Bechthold A. Function of glycosyltransferase genes involved in urdamycin A biosynthesis. Chemistry & Biology. 7: 133-42. PMID 10662691 DOI: 10.1016/S1074-5521(00)00079-X |
0.499 |
|
| Show low-probability matches. |